In March, two biotechnology companies were given the greenlight by the Food and Drug Administration, or FDA, to conduct trials transplanting genetically-modifie ...

New UCLA research conducted using mouse models and human genetic data has uncovered a critical factor that determines how ...

Vanrafia reduces proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). It has a wholesale acquisition cost ...

Key takeawaysUCLA researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as ...

Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with ...

CEO Stephen Glover said, “ZyVersa is developing Cholesterol Efflux Mediator VAR 200 for treatment of chronic kidney diseases, initially ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...